| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Novo Nordisk retains around 60% of the list price for its diabetes and obesity medications, Ozempic and Wegovy, after rebates a...
The updated employment figures have heightened concerns about Denmark's economy becoming excessively dependent on Novo.
European equities up, ECB likely to cut rates in June, traders confident. Euro slightly higher. Top performers: RWE, Bayer, VW,...
A team of Chinese scientists has successfully cured a patient's diabetes using cell therapy, marking a global first.
Elon Musk predicts that Novo Nordisk's weight-loss drug Ozempic will eventually become very cheap, following its depiction ...
- Bloomberg TV Interview
Novo Nordisk's Ozempic was used on 3,533 patients; results show a 24% reduction in kidney disease progression.
-Reuters
Weight loss drugs get the new parody treatment in a "South Park" streaming special.
